Candonilimab

A phase 2 trial demonstrated that the combination of cadonilimab and lenvatinib achieved a 42.9% objective response rate in patients with advanced endometrial cancer who progressed after platinum-based chemotherapy.

Neoadjuvant short-course radiation therapy (SCRT) with cadonilimab and chemotherapy demonstrated a 37% pathological complete response (pCR) rate in pMMR/MSS locally advanced rectal cancer.

The multispecific antibodies market has surpassed $8.6 billion in sales as of Q3 2024, with 16 approved therapies demonstrating efficacy across oncology and other therapeutic areas.

The addition of cadonilimab to platinum-based chemotherapy, with or without bevacizumab, significantly improved progression-free survival (PFS) in patients with advanced cervical cancer.

The Phase III COMPASSION-16 trial demonstrated that adding cadonilimab to chemotherapy and bevacizumab significantly improved outcomes in recurrent or metastatic cervical cancer.